|
12 Companies |
|
7 Products |
|
7 Products |
|
3 Mechanisms of Action |
|
1 Trial |
|
106 News |
|
| 12» |
- | NN1213 / Novo Nordisk
Enrollment change, Trial completion date, Trial termination: IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis (clinicaltrials.gov) - Aug 29, 2018
P=N/A, N=2, Terminated, Sponsor: Asan Medical Center
N=90 --> 2 | Trial completion date: Dec 2018 --> Jun 2018 | Recruiting --> Terminated; low enrollment rate
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Diagnostic of Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Feb 5, 2018
P=N/A, N=316, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
N=90 --> 2 | Trial completion date: Dec 2018 --> Jun 2018 | Recruiting --> Terminated; low enrollment rate Recruiting --> Completed | N=500 --> 316 | Trial primary completion date: Sep 2010 --> Jul 2015 | Trial completion date: Nov 2013 --> Jul 2017
- | Cubicin (daptomycin) / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date: DAPTODP: Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection (clinicaltrials.gov) - Jan 25, 2018
P=N/A, N=8, Completed, Sponsor: University Hospital, Caen
Recruiting --> Completed | N=500 --> 316 | Trial primary completion date: Sep 2010 --> Jul 2015 | Trial completion date: Nov 2013 --> Jul 2017 Recruiting --> Completed | N=12 --> 8 | Trial primary completion date: Sep 2017 --> Dec 2017
- | Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial primary completion date: Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Jan 9, 2018
P3, N=100, Recruiting, Sponsor: Sherief Abd-Elsalam
Recruiting --> Completed | N=12 --> 8 | Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: Dec 2017 --> Dec 2023
- | carvedilol / Generic mfg., propranolol / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: PREDESCI: Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal (clinicaltrials.gov) - Aug 22, 2017
P4, N=201, Completed, Sponsor: Fundaci
Trial primary completion date: Dec 2017 --> Dec 2023 Recruiting --> Completed | Initiation date: Sep 2009 --> Jan 2010 | Trial primary completion date: Sep 2011 --> Jul 2015
- | Enrollment change, Trial termination, Trial primary completion date: INFECIR2: The INFECIR-2 Albumin Prevention Study (clinicaltrials.gov) - May 18, 2017
P4, N=136, Terminated, Sponsor: EASL - CLIF Consortium
Recruiting --> Completed | Initiation date: Sep 2009 --> Jan 2010 | Trial primary completion date: Sep 2011 --> Jul 2015 N=512 --> 136 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Dec 2016; Low recruitment rate and expiration of the study drug
- | Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Enrollment change, Trial withdrawal: Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients (clinicaltrials.gov) - Apr 25, 2017
P3, N=0, Withdrawn, Sponsor: Seoul National University Hospital
N=512 --> 136 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Dec 2016; Low recruitment rate and expiration of the study drug N=56 --> 0 | Recruiting --> Withdrawn
- Cubicin (daptomycin) / Merck (MSD)
Phase classification, Trial primary completion date: DAPTODP: Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=12, Recruiting, Sponsor: University Hospital, Caen
N=56 --> 0 | Recruiting --> Withdrawn Phase classification: P2 --> P=N/A | Trial primary completion date: Sep 2015 --> Sep 2017
- ciprofloxacin oral / Generic mfg., norfloxacin / Generic mfg.
Trial completion: Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention (clinicaltrials.gov) - Dec 28, 2016
P4, N=124, Completed, Sponsor: Korea University
Phase classification: P2 --> P=N/A | Trial primary completion date: Sep 2015 --> Sep 2017 Recruiting --> Completed
- trimethoprim/sulfamethoxazole / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: VSL#3 and Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Oct 28, 2016
P2, N=10, Terminated, Sponsor: Nottingham University Hospitals NHS Trust
Recruiting --> Completed N=51 --> 10 | Recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Oct 2014; Unable to obtain QP release certification from the manufacturer (VSL3) for shipment of IMP
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial primary completion date: Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Oct 18, 2016
P3, N=100, Recruiting, Sponsor: Sherief Abd-Elsalam
N=51 --> 10 | Recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Oct 2014; Unable to obtain QP release certification from the manufacturer (VSL3) for shipment of IMP Trial primary completion date: Dec 2016 --> Dec 2017
- Trial completion, Trial primary completion date: Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis (clinicaltrials.gov) - Jul 28, 2016
P4, N=325, Completed, Sponsor: Chinese University of Hong Kong
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Apr 2015
- Trial completion, Enrollment change: Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure (clinicaltrials.gov) - Jul 23, 2016
P=N/A, N=175, Completed, Sponsor: Institute of Liver and Biliary Sciences, India
Active, not recruiting --> Completed | Trial primary completion date: Apr 2016 --> Apr 2015 Recruiting --> Completed | N=60 --> 175
- ||| Trial completion, Enrollment change, Trial primary completion date: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis (clinicaltrials.gov) - Jun 29, 2016
P=N/A, N=244, Completed, Sponsor: Pfizer
Recruiting --> Completed | N=60 --> 175 Recruiting --> Completed | N=200 --> 244 | Trial primary completion date: Feb 2016 --> May 2016
- Trial completion, Trial primary completion date, Surgery: Impact of Early Peri-operative Use of Polymyxin-B Hemoperfusion in Septic Patients Undergoing Emergent Abdominal Surgery (clinicaltrials.gov) - May 13, 2016
P=N/A, N=30, Completed, Sponsor: University Hospital, Geneva
Recruiting --> Completed | N=200 --> 244 | Trial primary completion date: Feb 2016 --> May 2016 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial primary completion date: Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Mar 10, 2016
P3, N=100, Recruiting, Sponsor: Sherief Abd-Elsalam
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date: INFECIR2: The INFECIR-2 Albumin Prevention Study (clinicaltrials.gov) - Feb 17, 2016
P4, N=512, Recruiting, Sponsor: EASL - CLIF Consortium
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2017
- Trial completion: Taurolock for Preventing Bacterial Peritonitis During Renal Insufficiency (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=150, Completed, Sponsor: Centre Hospitalier Universitaire de N?mes
Trial primary completion date: Dec 2015 --> Dec 2017 Active, not recruiting --> Completed
- | Trial completion: DURAPOP: Duration of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in ICU (clinicaltrials.gov) - Dec 10, 2015
P3, N=244, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| ampicillin/sulbactam / Generic mfg.
Trial completion: Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration - (clinicaltrials.gov) - Nov 16, 2015
P=N/A, N=986, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enrollment open: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis (clinicaltrials.gov) - Oct 29, 2015
P=N/A, N=200, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | Trial completion, Enrollment change: SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection (clinicaltrials.gov) - Oct 6, 2015
P3, N=518, Completed, Sponsor: National Institute of General Medical Sciences (NIGMS)
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | N=1120 --> 518
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial primary completion date: Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Sep 24, 2015
P3, N=100, Recruiting, Sponsor: Sherief Abd-Elsalam
Active, not recruiting --> Completed | N=1120 --> 518 Trial primary completion date: Jun 2015 --> Dec 2015
- || Trial initiation date: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis (clinicaltrials.gov) - Aug 28, 2015
P=N/A, N=200, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Jun 2015 --> Dec 2015 Initiation date: Aug 2012 --> Apr 2012
- || Phase classification, Trial initiation date, Trial primary completion date: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=200, Active, not recruiting, Sponsor: Pfizer
Initiation date: Aug 2012 --> Apr 2012 Phase classification: P4 --> P=N/A | Initiation date: Mar 2012 --> Aug 2012 | Trial primary completion date: Jul 2015 --> Feb 2016
- | Trial completion, Trial primary completion date: RNTCP-DOTS: Treatment Duration for Abdominal Tuberculosis (clinicaltrials.gov) - Jul 6, 2015
P3, N=197, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
Phase classification: P4 --> P=N/A | Initiation date: Mar 2012 --> Aug 2012 | Trial primary completion date: Jul 2015 --> Feb 2016 Recruiting --> Completed | Trial primary completion date: Jul 2008 --> Jul 2012
- Enrollment change, Trial termination, Trial primary completion date: PerProMe: Prophylactic Mesh Implantation in Patients With Peritonitis for the Prevention of Incisional Hernia (clinicaltrials.gov) - Jun 16, 2015
P=N/A, N=5, Terminated, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Completed | Trial primary completion date: Jul 2008 --> Jul 2012 N=80 --> 5 | Recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Apr 2015; Recruitment problems due to very restricted inclusion criteria
- ||| ampicillin/sulbactam / Generic mfg.
Enrollment closed, Trial primary completion date: Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration - (clinicaltrials.gov) - Jun 12, 2015
P4, N=1000, Active, not recruiting, Sponsor: Pfizer
N=80 --> 5 | Recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Apr 2015; Recruitment problems due to very restricted inclusion criteria Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Jul 2015
- ||| Enrollment closed, Trial primary completion date: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis (clinicaltrials.gov) - Apr 20, 2015
P4, N=214, Active, not recruiting, Sponsor: Pfizer
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Jul 2015 Completed --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Sep 2015
- Trial primary completion date: Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=60, Recruiting, Sponsor: Institute of Liver and Biliary Sciences, India
Completed --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Sep 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial primary completion date: Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Apr 14, 2015
P3, N=100, Recruiting, Sponsor: Sherief Abd-Elsalam
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Feb 2015 --> Jun 2015
- | Enrollment closed: DURAPOP: Duration of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in ICU (clinicaltrials.gov) - Apr 1, 2015
P3, N=244, Active, not recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Feb 2015 --> Jun 2015 Recruiting --> Active, not recruiting
- | ampicillin/sulbactam / Generic mfg.
Phase classification: Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration - (clinicaltrials.gov) - Mar 31, 2015
P4, N=1000, Enrolling by invitation, Sponsor: Pfizer
Recruiting --> Active, not recruiting Phase classification: P=N/A --> P4
- mupirocin / Generic mfg.
Trial completion: Use of Ointments in Prevention of Catheter Related Infections in PD (clinicaltrials.gov) - Mar 18, 2015
P4, N=200, Completed, Sponsor: University Health Network, Toronto
Phase classification: P=N/A --> P4 Active, not recruiting --> Completed
- Enrollment closed: Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis (clinicaltrials.gov) - Feb 6, 2015
P4, N=300, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=162, Completed, Sponsor: University of Lausanne Hospitals
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Biomarker, Trial completion, Trial primary completion date: The Value of PSP in Predicting Outcome in ICU Surgical Peritonitis Patients (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=137, Completed, Sponsor: University of Magdeburg
Recruiting --> Completed Enrolling by invitation --> Completed | Trial primary completion date: Dec 2011 --> Dec 2014
- Enrollment change, HEOR: Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Dec 5, 2014
P4, N=8, Terminated, Sponsor: University of Virginia
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2011 --> Dec 2014 N=116 --> 8
- |||||| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Enrollment open: Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients (clinicaltrials.gov) - Dec 5, 2014
P3, N=56, Recruiting, Sponsor: Seoul National University Hospital
N=116 --> 8 Not yet recruiting --> Recruiting
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial primary completion date: Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Nov 18, 2014
P3, N=100, Recruiting, Sponsor: Sherief Abd-Elsalam
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2014 --> Feb 2015
- Cubicin (daptomycin) / Merck (MSD)
Enrollment change, Trial termination: Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Oct 17, 2014
P2/3, N=32, Terminated, Sponsor: University of Padova
Trial primary completion date: Jul 2014 --> Feb 2015 N=60 --> 32 | Recruiting --> Terminated; Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group.
- Enrollment open, Trial primary completion date: PerProMe: Prophylactic Mesh Implantation in Patients With Peritonitis for the Prevention of Incisional Hernia (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=80, Recruiting, Sponsor: University Hospital Inselspital, Berne
N=60 --> 32 | Recruiting --> Terminated; Decision of independent monitoring committee after interim analysis: Risk of failure significantly higher in ceftazidime group. Suspended --> Recruiting | Trial primary completion date: Aug 2014 --> Jul 2016
- Cubicin (daptomycin) / Merck (MSD)
Enrollment open: DAPTODP: Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection (clinicaltrials.gov) - Oct 10, 2014
P2, N=12, Recruiting, Sponsor: University Hospital, Caen
Suspended --> Recruiting | Trial primary completion date: Aug 2014 --> Jul 2016 Not yet recruiting --> Recruiting
- | ampicillin/sulbactam / Generic mfg.
Phase classification: Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration - (clinicaltrials.gov) - Sep 9, 2014
P=N/A, N=1000, Enrolling by invitation, Sponsor: Pfizer
Not yet recruiting --> Recruiting Phase classification: P4 --> P=N/A
- Trial initiation date: INFECIR2: The INFECIR-2 Albumin Prevention Study (clinicaltrials.gov) - Aug 30, 2014
P4, N=512, Ongoing, Sponsor: Fundacio Clinic per a la recerca biomedica`Medical University of Graz, Department of Internal Medicine, Division of Gastroenterology and Hepatology
Phase classification: P4 --> P=N/A Initiation date: May 2014 --> Oct 2013
- Enrollment open, Trial primary completion date: INFECIR2: The INFECIR-2 Albumin Prevention Study (clinicaltrials.gov) - Aug 29, 2014
P4, N=512, Recruiting, Sponsor: EASL - CLIF Consortium
Initiation date: May 2014 --> Oct 2013 Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2014 --> Dec 2015
- Trial initiation date: INFECIR2: The INFECIR-2 Albumin Prevention Study (clinicaltrials.gov) - Aug 19, 2014
P4, N=512, Ongoing, Sponsor: Fundacio Clinic per a la recerca biomedica`Medical University of Graz, Department of Internal Medicine, Division of Gastroenterology and Hepatology
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2014 --> Dec 2015 Initiation date: Mar 2014 --> Oct 2013
- |||| Trial completion, Enrollment change, Trial primary completion date: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis (clinicaltrials.gov) - Jul 16, 2014
P4, N=214, Completed, Sponsor: Pfizer
Initiation date: Mar 2014 --> Oct 2013 Enrolling by invitation --> Completed | N=3000 --> 214 | Trial primary completion date: Jul 2014 --> Mar 2014
- Enrollment open: IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=90, Recruiting, Sponsor: Asan Medical Center
Enrolling by invitation --> Completed | N=3000 --> 214 | Trial primary completion date: Jul 2014 --> Mar 2014 Not yet recruiting --> Recruiting
- Clinical: IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=90, Not yet recruiting, Sponsor: Asan Medical Center